Markets:

Overview

News

Currencies

International

Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

34.69 -0.34 (-0.98%)

Streaming Delayed Price Updated: 1:05 PM EDT, Jul 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Why Is Roivant Sciences (ROIV) Stock Up Today? ↗

October 23, 2023

ROIV stock barely moved after the Roche deal, reflecting a down market and lack of movement on Roivant's other drug candidates.

Via InvestorPlace

Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space ↗

October 23, 2023

Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases.

Via Investor's Business Daily

Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal ↗

October 23, 2023

Roche Holding AG (OTC: RHHBY) inked a deal to acquire

Via Benzinga

Why Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving Premarket ↗

October 23, 2023

Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 151.7% to $0.2190 in pre-market trading after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set...

Via Benzinga

What 8 Analyst Ratings Have To Say About Roivant Sciences ↗

October 17, 2023

Via Benzinga

Analyst Expectations for Roivant Sciences's Future ↗

September 18, 2023

Via Benzinga

What 9 Analyst Ratings Have To Say About Roivant Sciences ↗

August 31, 2023

Via Benzinga

8 Analysts Have This to Say About Roivant Sciences ↗

August 15, 2023

Via Benzinga

Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

October 23, 2023

U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant

October 23, 2023

From Roivant Sciences

Via GlobeNewswire

Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer

October 13, 2023

From Covant Therapeutics

Via GlobeNewswire

Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble. ↗

October 04, 2023

The deal leans into the emerging TL1A drug class, potentially rivaling Roivant and Merck.

Via Investor's Business Daily

3 No-Brainer Growth Stocks to Buy in October ↗

October 01, 2023

These three top mid-cap stocks could be poised for a long-tailed growth spurt.

Via The Motley Fool

Why Immunovant Stock Is Bolting Higher Today ↗

September 27, 2023

The company may have best-in-class autoimmune disease therapy under its roof.

Via The Motley Fool

Johnson Controls International To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Wednesday ↗

September 27, 2023

Keybanc cut the price target for Danaher Corporation (NYSE: DHR) from $325 to $300. Keybanc analyst Paul Knight maintained an Overweight rating. Danaher shares rose 0.6% to $248.75 in pre-market...

Via Benzinga

Roivant Stock Price Outlook: Strong Pipeline Is A Catalyst ↗

September 27, 2023

Roivant Sciences has 12 drugs in its pipeline. The company’s Immunovant subsidiary reported strong results for its drug. Roivant is in talks with Roche to sell its Chron’s disease for $7 billion.

Via Talk Markets

Why Shares of Immunovant Are Soaring on Tuesday ↗

September 26, 2023

Immunovant sees strong potential for an autoimmune disorder therapy.

Via The Motley Fool

Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

September 26, 2023

Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi...

Via Benzinga

Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday ↗

September 26, 2023

U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Why Is Autoimmune Disease-Focused Immunovant Stock Trading Higher Today? ↗

September 26, 2023

Immunovant Inc (NASDAQ: IMVT), a unit of Roivant Sciences Ltd (NASDAQ: ROIV), announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in Immunoglobulin G (IgG)...

Via Benzinga

These 2 Biotech Stocks Are Bucking a Down Market Tuesday ↗

September 26, 2023

Stock index futures pointed to a lower open on Wall Street Tuesday morning.

Via The Motley Fool

Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

September 26, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant Announces Completion of Redemption of its Outstanding Warrants

September 11, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant Sciences: Is Vivek Ramaswamy’s Biotech Stock A Buy? ↗

September 10, 2023

Roivant Sciences stock price has entered a major bull run as investors remain optimistic about the company’s future. The shares surged to a high of $12.67 on Friday, reaching its highest level since...

Via Talk Markets

Vivek Ramaswamy's Parallels With Warren Buffett Run Deeper Than Wanting To Make Roivant The 'Berkshire Hathaway Of Drug Development' ↗

September 04, 2023

Presidential hopeful Vivek Ramaswamy and Warren Buffett may share different political ideologies but they have at least a couple of things in common.

Via Benzinga

2 Supercharged Growth Stocks Billionaires Can't Stop Buying ↗

August 28, 2023

A top hedge fund has been steadily buying these two growth stocks in 2023.

Via The Motley Fool

If You Invested $1000 In Vivek Ramaswamy-Founded Roivant When He Declared Presidential Bid, Here's How Much You'd Have Now ↗

August 25, 2023

Roivant stock has outperformed the broader market and the biotech sector this year, mirroring the rise in the fortunes of its founder Vivek Ramaswamy.

Via Benzinga

Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants

August 17, 2023

From Roivant Sciences

Via GlobeNewswire

Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales ↗

August 14, 2023

The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease.

Via Investor's Business Daily

Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update

August 14, 2023

From Roivant Sciences

Via GlobeNewswire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.